Bundles
Retatrutide Value Bundle
Includes 2 × Retatrutide 10mg + BAC Water 3ml + 0.5 mL Graduated Syringes 20 Pack
$320.96bought separatelySave $50.97Free express shipping
SKU 44595
$269.99
Buy Retatrutide in Australia
In Australia, Retatrutide is from $139.99 a vial at Australian Research Peptides, which sells it to laboratories and researchers and has it in stock; business-day orders paid before 12pm Sydney time are dispatched that day. Retatrutide vials hold 10 mg, 20 mg or 30 mg of HPLC-tested freeze-dried powder, sealed in glass and shipped to every state and territory. The single synthetic chain, built on a GIP backbone, carries a C20 fatty di-acid that binds albumin. In laboratory assays it binds the GIP, GLP-1 and glucagon receptors together, and it is studied in metabolic research. In vitro research purposes only.
Metabolic Research · Lyophilised Powder · HPLC-tested · SKU 37501
$139.99
1
Presentation
10 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Metabolic Research
Same-day dispatch on business-day orders completed before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. ARP gives no usage, medical or therapeutic guidance of its own.
Retatrutide · 10 mg
$139.99
Retatrutide bundles
Bundles
Retatrutide 20mg Starter Bundle
Includes Retatrutide 20mg + BAC Water 3ml + 0.5 mL Graduated Syringes 20 Pack
$260.97bought separatelySave $20.98Free express shipping
SKU 46426
$239.99
Bundles
Retatrutide Mega Bundle
Includes 3 × Retatrutide 10mg + 2 × BAC Water 3ml + 3 × 0.5 mL Graduated Syringes 20 Pack
$526.92bought separatelySave $106.93Free express shipping
SKU 41053
$419.99
Bundles
Retatrutide 4-Vial Bundle
Includes 4 × Retatrutide 10mg
$559.96bought separatelySave $109.97Free express shipping
SKU 43729
$449.99
About Retatrutide
Retatrutide is studied in metabolic research. Eli Lilly developed the molecule and has carried it from early work through large late-stage studies. In laboratory receptor assays it binds the GIP, GLP-1 and glucagon receptors. That triple target separates it from the single-receptor GLP-1 analogues, which act at GLP-1 alone, and from the dual GIP/GLP-1 agonists, which act at two.
The molecule is one continuous chain of 39 amino acids, engineered from a GIP peptide backbone. The chain carries a C20 fatty di-acid, meaning a twenty-carbon fatty group bonded onto it. That group is described as binding albumin in blood, which is the design feature reported to make the molecule long-acting.
Australian Research Peptides supplies retatrutide as a freeze-dried solid, white to off-white, sealed in a tamper-evident glass vial. It is also written and searched as reta or retat. The material is a laboratory reference compound, characterised for benchwork in glassware and cell culture rather than for any use in a living subject.
In Australia, retatrutide is listed by Australian Research Peptides in three vial strengths — 10 mg, 20 mg and 30 mg — each with its own stock code and its own batch certificate. Anyone searching retatrutide Australia, reta peptide, or the numeric R3ta will land on the same triple-agonist compound under all of those names. Vials are held and posted domestically rather than shipped in from overseas, so an order is not waiting on international freight. Purity is assayed by HPLC, and the measured figure is published on each strength's own certificate rather than as a blanket claim about the line.
BAC water (bacteriostatic water) is also in our range.
The peptide calculator works out the mg/mL concentration of a reconstituted vial.
Retatrutide specifications, storage and shipping
- Compound: Retatrutide
- Also known as: Retatrutide (LY3437943)
- Class: Synthetic peptide; GIP / GLP-1 / glucagon receptor triple agonist
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (37501), 20 mg (33410), 30 mg (39966)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed to a minimum of 99% purity — the measured result is stated on the published Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Certificates: issued by Janoshik, an independent laboratory, and published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Retatrutide is HPLC-tested for purity and confirmed by mass spectrometry for identity. The full laboratory report is published in the COA library. Retatrutide is tested by Janoshik, an independent laboratory, commissioned by the manufacturer rather than by Australian Research Peptides.
- Retatrutide 10 mg: assayed purity 99.861% · measured content 10.97 mg · laboratory batch 2026-06 · analysed 22 June 2026
- Retatrutide 20 mg: assayed purity 99.735% · measured content 19.58 mg · laboratory batch 2026-06 · analysed 22 June 2026
- Retatrutide 30 mg: assayed purity 99.482% · measured content 33.05 mg · analysed 17 March 2026
Business-day orders before 12pm Sydney time are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about Retatrutide
This question guide from Australian Research Peptides covers Retatrutide in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
Australian Research Peptides supplies Retatrutide within Australia, and orders in before 12pm Sydney time on a business day go out the same afternoon. Three vial strengths are listed, each with its own RET stock code. Express Post or standard tracked post covers every state and territory.
Retatrutide is sold online in Australia by Australian Research Peptides, a domestic supplier that lists the compound in three vial strengths. Payment is by PayID or a bank transfer, with the order reference quoted in the payment description so the money can be matched. Every parcel travels inside Australia.
Retatrutide ships from within Australia, so there is no customs leg. Express Post runs 1–2 business days to ACT, NSW, VIC and SA, 1–3 to Queensland, and 2–4 to WA and the Northern Territory. Standard tracked post runs 2–5. Those are capital-city transit times counted after lodgement, and regional addresses sit beyond them.
A Retatrutide vial comes without a diluent, because it contains freeze-dried peptide and nothing else, with no liquid and no laboratory consumables inside the sealed glass. The solvent, glassware and measuring equipment are chosen by the laboratory to suit its own method, and the vial is supplied for in vitro research purposes only.
Retatrutide holds no approval from the US Food and Drug Administration, nor from any other medicines regulator anywhere. Eli Lilly still describes it as an investigational molecule. Its development programme is still running, which is a step toward a submission rather than a licence in itself. Research-grade powder sits a further step removed, assessed by no one at all.
Identity, names and exact format
Retatrutide is a synthetic peptide of 39 amino acids, developed by Eli Lilly under the code LY3437943 (Coskun 2022) and studied in metabolic research. It is described as reaching the GIP, GLP-1 and glucagon receptors together, where single- and dual-receptor designs are the norm. The chain is one engineered molecule rather than a mixture of separate peptides, built on a GIP backbone with a twenty-carbon fatty di-acid bonded onto it. That fatty group is the part that makes it long-acting.
Published Retatrutide studies measure receptor binding in the laboratory and metabolic endpoints in registered clinical trials. Retatrutide is an investigational compound and is not approved by the TGA or any other regulator for any use. In receptor assays the molecule binds three targets (GLP-1, GIP and glucagon), where single- and dual-receptor peptides bind one or two. Australian Research Peptides does not restate published trial figures on this page, because the material those studies used is not the material in this vial; what ARP publishes instead is the batch certificate.
Yes — Retatrutide is freeze-dried, and ten milligrams of dried peptide occupies almost no space: commonly a thin white disc, or a faint film on the glass base that overhead lighting washes out entirely. Tilting the container slowly against a dark surface usually reveals it. The 20 mg and 30 mg strengths carry two and three times that solid, so they read as an obvious cake. Weight rather than visible bulk is what batch analysis records.
Retatrutide and tesamorelin do not compete for the same receptors — retatrutide acts on the GIP, GLP-1 and glucagon receptors, tesamorelin on the growth-hormone-releasing hormone receptor — which is the reasoning behind listing them as a bundle. That is an argument from how each molecule works, not a tested result. No published study has run the pair together, so any interaction between them has never been measured.
Research context and evidence
Reta is the everyday short form of Retatrutide, and the compound is also searched as Reta Peptide, R3ta, Reda Peptide, Ratatouille Peptide and retatrudie — all of them one triple-agonist research compound, not five. The short form Reta is what the research literature uses. The numeric R3ta peptide circulates in online research communities. Reda peptide, Ratatouille peptide and retatrudie are autocorrect slips rather than names anyone writes on purpose.
Retatrutide reaches three receptor targets at once. Published laboratory work describes the molecule binding at the GIP, GLP-1 and glucagon receptors, a combination that single- and dual-receptor designs do not have. Bonded onto the chain is a C20 fatty di-acid — a twenty-carbon fatty tail — and it binds albumin, the most common protein in blood, which is the structural feature the molecule was engineered around. Every statement here describes binding measured in glassware, not anything occurring in a living subject.
Retatrutide has a published research literature in metabolic science, developed by Eli Lilly and reported in peer-reviewed journals (Jastreboff 2023). Australian Research Peptides publishes none of those figures on this page, because the material described in that literature is not the material in this vial. What ARP publishes instead is the batch's own certificate: identity and assay purity, measured by HPLC and confirmed by mass spectrometry, with the document itself in the CoA library.
A retatrutide vial holds one substance and nothing else. No carrier, no second peptide, no liquid. It is a freeze-dried solid, white to off-white, behind a tamper-evident seal. The C20 fatty di-acid is chemically bonded into the peptide chain rather than added alongside it, which is why the dry contents count as a single compound. The milligram figure on the listing is peptide weight.
Retatrutide has 39 amino acids in one continuous synthetic chain. It is a single engineered molecule, not a blend of separate peptides mixed together. The chain is built from a GIP peptide backbone with a C20 fatty di-acid attached to it. No residue-by-residue sequence appeared in the public records checked. The milligram figure on the vial is weight, not a residue count.
Retatrutide should be kept sealed, cold and dry, away from moisture. The freeze-dried powder pulls water out of the air, so let a cold vial reach room temperature before you break the seal. Bachem's peptide handling guidance puts lyophilised material below -15 C for long-term storage and 4 C for short periods. Colder is better, and that guidance prefers -50 C or lower for long holdings.
Retatrutide is reconstituted with a suitable diluent added straight into the sealed vial. Let the liquid run down the inside glass wall rather than onto the powder. Swirl until clear and never shake. Australian Research Peptides supplies the vial dry and publishes no fill volume for it; the diluent is chosen by the laboratory for its own method.
Reconstituted retatrutide keeps at 2 to 8 °C for eight to twelve weeks. That is the storage condition Australian Research Peptides publishes for every HPLC Verified line it sells. Keep the solution dark, and never refreeze one that has thawed. For holds longer than that, Bachem and GenScript both advise splitting it into single-use aliquots and freezing them below -15 °C.
Australian Research Peptides publishes no fill volume for Retatrutide and there is no single correct one. What the diluent changes is the concentration of the solution, never the amount of peptide, which is fixed at the milligrams printed on the label and is the same whether a little liquid goes in or a lot.
Handling, storage and measurements
Trapped air explains almost every cloudy Retatrutide vial. Directing the stream onto the cake, or shaking rather than swirling, whips tiny air bubbles through the liquid, and they scatter light exactly as real cloudiness does, then rise and disperse within a few minutes at rest. Cold glass slows the powder dissolving as well. Haze still present after ten minutes at room temperature points instead to solid that has not dissolved, or to peptide that has clumped together, and the 30 mg strength takes longest because it holds three times the material.
Retatrutide arrives as a dry solid and needs a liquid to bring it into solution for laboratory work, usually an aqueous diluent chosen to suit the method. Diluent is simply the word for whatever liquid dissolves a dried solid back into solution. Nothing in the vial is already wet, because the fatty group is bonded to the chain rather than floating loose.
Australian Research Peptides Pty Ltd, trading as ARP, is the supplier of retatrutide in Australia, an Australian company dispatching from Sydney. The compound is catalogued under Metabolic Research by its development code LY3437943, and its purity is tested by HPLC. PayID and bank transfer are the routes accepted — no buy-now-pay-later and no crypto.
Retatrutide is priced per vial in Australian dollars, with a separate figure for each of the three strengths. Australian Research Peptides holds all three figures in its live catalogue record, so the current one governs rather than any number fixed in prose. The 20 mg and 30 mg vials each clear the free standard-post threshold on their own. Retatrutide holds the HPLC Verified grade: its published laboratory certificates report a purity figure measured by HPLC. Postage is charged separately, by the service chosen.
The Retatrutide 30 mg vial holds three times the peptide of the 10 mg one, in a single container. A larger requirement can be met from one vial instead of several, and all of it comes from one batch. The compound, the powder and the testing are identical across the three strengths. Only the quantity changes.
Retatrutide's cost per milligram falls as the vial gets larger, so the 30 mg vial is the cheapest per milligram and the 10 mg the dearest. Each strength's figure is rendered live from Australian Research Peptides' catalogue data. Against that, a larger vial holds more solution once mixed and takes longer to work through, which matters because reconstituted peptide has a shelf life.
The 20 mg vial suits work that has already moved past a first evaluation and is set to continue. It holds twice the peptide of the 10 mg vial at a lower cost per milligram, halves the number of reconstitutions needed for the same total quantity, and removes the risk of running short partway through a series of experiments. The compound, the purity standard and the batch testing are identical across the two formats. The 10 mg vial is the entry point; the 20 mg is the working stock.
Retatrutide is one of the few lines where a single vial can qualify for free post: the two larger strengths each clear the Standard tracked post threshold unaided, and only the largest also reaches the separate, higher Express Post one. Two of the smallest vials together clear the standard threshold as well. Australian Research Peptides judges every order against both thresholds on its pre-discount goods value.
Testing and batch documents
Retatrutide reaches three receptors and the dual agonists reach two. The dual agonists act at the GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity on top of those two, and that third target is the entire difference between them. Australian Research Peptides lists Retatrutide for laboratories and researchers.
Retatrutide is described as acting at three receptors, one more than the dual GIP/GLP-1 agonists and two more than the single-receptor GLP-1 analogues. Those analogues are described as acting at GLP-1 alone; the dual agonists at GLP-1 and GIP; Retatrutide at GLP-1, GIP and glucagon. Australian Research Peptides does not restate published trial outcomes for any of the three on this page. The glucagon receptor arm, which is associated with energy expenditure, is the structural difference Retatrutide has and the other two do not.
The three Retatrutide listings hold the same material in different quantities. The number is milligrams of peptide sitting in the glass. Colour, container, closure and the testing method do not change between them. Australian Research Peptides gives every strength its own page and its own stock code, and all three sit under one parent listing.
Ordering, payment and Australian delivery
Retatrutide is not approved for therapeutic use by the TGA, or by any other regulator worldwide. Eli Lilly describes it as an investigational molecule, legally available only to people enrolled in its own clinical trials. Australian Research Peptides supplies it as a laboratory research chemical, not as a medicine, and not for use in people or animals. Check your own obligations before handling it.
No launch date for retatrutide has been published, and nobody can honestly supply one. Eli Lilly's development programme is still running, but a regulator must still receive a complete dossier, review it and decide, and refusal remains possible at that point. Any seller naming a specific year is guessing. Until some authority grants a licence, the compound stays investigational.
Retatrutide is banned for any tested athlete. Still investigational, with no approval from a government health regulator, it falls inside category S0 — the sweep capturing investigational molecules — and that ban runs year-round, not merely on competition day. Australian competitors are governed by Sport Integrity Australia, where a positive sample counts whatever the athlete intended.
Retatrutide remains an investigational molecule rather than an approved commercial medicine on sale to the Australian public. Australian Research Peptides does not supply it as a compounded prescription item or a pharmacy medicine, and because no regulator has approved it, no Australian compounding pharmacy can lawfully make it up either — what ARP supplies is research-grade freeze-dried powder for lawful in vitro laboratory work only. Eli Lilly still describes the molecule as investigational with its development programme running, so commercial release would depend on that programme finishing and a regulator then granting approval. No launch date has been published.
Access and regulatory questions
Retatrutide crossing the Australian border raises obligations for the importer, not the seller — the Therapeutic Goods Administration sets the rules covering unapproved goods and Border Force enforces them at the frontier. Australian Research Peptides removes the question by dispatching from Sydney rather than shipping across the border, so a customer's parcel never leaves the country. Anyone importing separately should read the TGA's guidance first.
Retatrutide batches supplied by Australian Research Peptides go through two separate analyses at an independent laboratory, commissioned by the manufacturer, before they are sold, one measuring purity and the other confirming identity. HPLC produces the purity figure. Mass spectrometry then establishes that the molecule really is retatrutide and not something that presents identically as a dry powder. Identity is the one that matters here, because a shortened chain or a stripped fatty group still looks like white powder.
A Retatrutide document applies only to the exact vial strength it names, not to the parent listing or a sibling strength. Never substitute a 10 mg, 20 mg or 30 mg document for another strength. A matching certificate is currently published for 10 mg, 20 mg and 30 mg. Open the 10 mg, 20 mg or 30 mg certificate.
Retatrutide analytical testing establishes three things: chromatographic purity, identity by mass, and the measured peptide content of the vial. The purity figure reports how much of the sample sits under the main peak, using the stated method. The mass result says whether that peak weighs what Retatrutide should weigh. The content figure is stated in milligrams for the exact strength tested, and is published per strength in ARP's certificate library. Retatrutide is supplied to laboratories and researchers for in vitro research purposes only.
Retatrutide is also known by Eli Lilly's development code LY3437943 and is indexed under that code in trial registries and NIH MeSH record C000729679. It is commonly shortened to "Reta" in everyday use, which is a contraction of the same name rather than a different compound. It is sometimes nicknamed "Triple G" because it acts at GIP, GLP-1 and glucagon receptors; that nickname is informal, not a separate compound name. The label "GLP-3" is a misnomer rather than a synonym because Retatrutide does not involve a third GLP peptide.
Retatrutide is described as acting at three receptors and the single-receptor GLP-1 peptides at one. Retatrutide is described in the literature as a triple agonist, at the GIP, GLP-1 and glucagon receptors. The GLP-1-only class is described as working at the GLP-1 receptor alone. They are separate molecules with different sequences and different weights, and Australian Research Peptides catalogues Retatrutide rather than that class.